Early Stage

BioHealthonomics is a pharmaceutical company developing a proprietary, industry unique technology for the treatment and prevention of migraine headaches.


Raised to Date: Raised: $36,600

Total Commitments ($USD)



Start Date


Close Date


Min. Goal
Max. Goal
Min. Investment


Security Type

Equity - Common

SEC Filing Type

RegCF    Open SEC Filing

Price Per Share


Pre-Money Valuation


Rolling Commitments ($USD)

Reporting Date


Days Remaining
% of Min. Goal
% of Max. Goal
Likelihood of Max
Avg. Daily Raise


# of Investors


Create a free account today to gain access to KingsCrowd analytics.
Year Founded



Healthcare & Pharmaceuticals

Tech Sector


Santa Monica, California

The throbbing. The nausea. The flickering lights, neck pains, and feeling like it will never end. When you get a migraine, life seems to stop.

BioHealthonomics is here to help. They are a pharmaceutical company developing an industry unique technology for the treatment and prevention of migraine headaches. Their technology addresses the root cause of the problem by targeting the histamine receptors found to be involved in migraine headaches. People susceptible to migraines have a tendency to release excess histamine when introduced to a stressor or trigger, which is what causes the headache. BioHealthonomics’ treatment helps prevent that release of excess histamine from happening. Less histamine means less migraines -- and who doesn’t want that?

So far, clinical studies have found their treatment works in over 80% of migraine patients, versus the traditional migraine treatment of using CGRP antibodies, which only works in 50% of patients. BioHealthonomics believes their technology is superior to CGRP antibodies both in terms of safety efficacy and cost standpoints, and they have a clear path for continuing to develop an extremely effective, side effects free treatment.

So far, they have two issued patents in the U.S. and patents pending in five additional markets. They’ve also entered into a strategic agreement with another pharmaceutical company to gain access to pre-clinical, phase I clinical, and chemistry, manufacturing, and controls data. This will save millions of dollars in development costs, as well as years in development time.

Migraines are the sixth most disabling disorder in the U.S., with over 30 million people suffering from them. In fact, $50 billion is lost each year because of medical expenses caused by headaches, reduced employee productivity, and absenteeism. The migraine product market is currently $3.4 billion, with projections to grow up to $10 billion in the next decade, and BioHealthonomics, with their industry unique treatment, is poised to be the leader in this market.

You could truly be on your way to being headache free. BioHealthonomics has the technology to make that dream a reality. A life without migraines….just imagine all of the possibilities.

“Who Should Be Interested in this Offer:”
If you’re someone who suffers from migraines, or if someone close to you does, then BioHealthonomics is worth your attention. They are offering a solution that addresses the root of the problem and has proven to be more successful than current available treatments. If you want to say goodbye to migraines (and possibly profit at the same time!), then investing in BioHealthonomics might just be the headache-free choice for you.
Create a free account today to gain access to KingsCrowd analytics.

Upgrade to gain access

Pay Monthly
Annually (Save 17%)


$12.42 /month
billed annually
Free portfolio tracking and KingsCrowd's quantitative ratings on all raises.
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings (excluding risk)
Advanced company search ( with ratings)
Markets page filters and historical industry data
Get Edge Annual

Edge Pro

$41.58 /month
billed annually
Full site access including KingsCrowd's qualitative analyst reports.
Plan Includes:
Everything in Edge, plus
Full access to detailed Analyst Reports (e.g. Top Deal, Deal to Watch, Neutral, and Underweight)
Search and filter based on Analyst Reports
In-depth risk ratings for every raise
Get Edge Pro Annual
Already a member? Log in here.
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.

Create your first portfolio

Create your own startup investment portfolio on KingsCrowd.

Track all of your startup investments in one place using our state-of-the-art portfolio tracker tools. To begin, create your first portfolio below.

Add to portfolio
BioHealthonomics on StartEngine
Platform: StartEngine
Security Type: Equity - Common
Valuation: $27,537,550
Price per Share: $50.00

Follow company

Follow BioHealthonomics on StartEngine

Buy BioHealthonomics's Deal Report

Warning: according to the close date for this deal, BioHealthonomics may no longer be accepting investments.

BioHealthonomics Deal Report

Get KingsCrowd’s comprehensive report on BioHealthonomics including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether BioHealthonomics is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the BioHealthonomics deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge Pro